



(51) International Patent Classification:

A61K 31/353 (2006.01) *A61K 31/724* (2006.01)

(21) International Application Number:

PCT/US2023/020798

(22) International Filing Date:

03 May 2023 (03.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/316,685 04 March 2022 (04.03.2022) US

(71) Applicant: **CAS PROPERTIES, LLC** [US/US]; 895 Dove Street, 3rd Floor, Newport Beach, California 92660 (US).(72) Inventors: **THEOHARIDES, Theoharis C.**; 895 Dove Street, 3rd Floor, Newport Beach, California 92660 (US). **ROUFS, James**; 895 Dove Street, 3rd Floor, Newport Beach, California 92660 (US). **HWANG, Paul**; 895 Dove Street, 3rd Floor, Newport Beach, California 92660 (US).(74) Agent: **DAVIS, Kevin J.**; 717 Texas Avenue, Suite 2100, Houston, Texas 77002 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ERIODICTYOL COMPOSITIONS AND METHODS





FIG. 1

(57) **Abstract:** Compositions and methods for the treatment or prevention of neurovascular inflammation and damage in a subject. The composition includes a pharmaceutically acceptable amount of eriodictyol and/or any pharmaceutically acceptable form, including salt, cocrystal, analog, or physically and/or chemically modified forms thereof.

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii))*